This poses a dilemma: with the introduction of CFTR modulator therapies, it is no longer the norm that pwCF will produce sputum spontaneously, leading to the James Lind Alliance research priority in CF: “What is the best way to diagnose lung infection when there is no sputum?” (61). Here, CFTR is linked to cystic fibrosis.